Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Thoracic 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × sapacitabine × Clear all
NCT00476554 2021-12-22

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

Cyclacel Pharmaceuticals, Inc.

Phase 2 Terminated
16 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT00885963 2021-12-22

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

Cyclacel Pharmaceuticals, Inc.

Phase 2 Terminated
62 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01253460 2019-09-06

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

M.D. Anderson Cancer Center

Phase 2 Terminated
18 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡